|Articles|August 29, 2012

New Antibacterial Coating for Sutures Could Reduce Infections After Surgery

Responding to an urgent need for better antibacterial coatings on surgical sutures, scientists are reporting the discovery of a new coating that is almost 1,000 times more effective than the most widely used commercial coating. Their report appears in the American Chemical Society's journal, Langmuir.

Professor Gregory Tew, who is from UMass-Amherst, and colleagues explain that infection at the site of surgical incisions is one of the most common post-surgical complications that keep patients hospitalized longer and boost hospital bills. The most common antibiotic coating contains triclosan, but its use in many consumer products over the years has led to the emergence of strains of bacteria that shrug off its effects. Triclosan also can be absorbed into the body, raising concerns about possible adverse health effects. Another downside to triclosan: It slows the growth of bacteria, but does not actually kill those already present. That's why the scientists turned to PAMBM, a new substance designed from naturally occurring antimicrobial peptides that can kill a wide range of bacteria. And because of the way it works, PAMBM has a very low chance of causing bacterial resistance and the emergence of so-called superbugs.

The report described laboratory tests in which PAMBM greatly reduced the amount of bacteria compared to triclosan. In a head-to-head test with triclosan-coated sutures, those coated with PAMBM were much more effective against bacteria. "As bacterial resistance to current agents continues to increase and with resistance to triclosan now documented, the discovery of new antimicrobial agents that remain active in biomedical device coatings is essential," say the researchers.


The authors acknowledge funding from the National Science Foundation.
 
Source: American Chemical Society  


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.